Nika Pharmaceuticals, Inc.
NIKA
$1.00
$0.000.00%
OTC PK
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 200.00 | 200.00 | 200.00 | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 200.00 | 200.00 | 200.00 | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | 200.00 | 200.00 | 200.00 | -- | -- |
SG&A Expenses | 141.90K | 136.70K | 138.40K | 111.20K | 64.80K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 141.90K | 136.70K | 138.40K | 111.20K | 64.80K |
Operating Income | -141.70K | -136.50K | -138.20K | -111.20K | -64.80K |
Income Before Tax | -141.70K | -136.50K | -138.20K | -111.20K | -64.80K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -0.14 | -0.14 | -0.14 | -0.11 | -0.06 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -141.70K | -136.50K | -138.20K | -111.20K | -64.80K |
EBIT | -141.70K | -136.50K | -138.20K | -111.20K | -64.80K |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Basic Shares Outstanding | 3.94B | 3.79B | 3.65B | 3.50B | 3.50B |
Average Diluted Shares Outstanding | 3.94B | 3.79B | 3.65B | 3.50B | 3.50B |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |